本研究通过回顾性分析137例tPSA处于4-10 ng/mL诊断灰区的患者，系统评估了游离前列腺特异性抗原密度（FPSAD）与前列腺影像报告和数据系统2.1版（PI-RADS v2.1）联合应用对临床显著前列腺癌（csPCa，定义为Gleason评分≥3+4）的诊断价值。结果表明，联合模型（AUC=0.829 ...

本研究针对重复前列腺活检中PI-RADS 3病变的诊断挑战，通过回顾性分析684例患者数据，发现PI-RADS 3是阴性活检的独立预测因子（OR 0.582），而PSA密度（PSAD）在PI-RADS 4-5病变中具有显著风险分层价值（62.4% vs 33.8%），在PI-RADS 3中则差异有限（20.7% vs 16.2%）。该研究为 ...

Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis.

Targeting PI-RADS 4 and 5 lesions for confirmatory biopsy improves detection of clinically significant cancer. The following article is part of conference coverage from the 2017 American Urological ...

Survival impact of initial local therapy selection for men under 60 with high risk prostate cancer. Prostate cancer (PCa) in 696 hypogonadal men with and without long-term testosterone therapy (TTh): ...

Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...

PI-RADS version 2.1 demonstrated improved detection of clinically significant prostate cancer in the transition zone. For detecting clinically significant prostate cancer (csPCa), prostate imaging ...